Norbrook

Norbrook, established in 1969, is a prominent veterinary pharmaceutical company headquartered in the United Kingdom. With a history spanning over five decades, the company has developed a strong reputation for its commitment to animal health and welfare. Norbrook operates across 16 locations globally, indicating a significant international presence and distribution network. Its core business revolves around the research, development, manufacturing, and marketing of a wide range of veterinary medicines and pharmaceutical products designed for both companion and farm animals. The company's product portfolio includes active pharmaceutical ingredients and finished dosage forms, serving diverse therapeutic areas within veterinary medicine. This focus on specialized pharmaceuticals positions Norbrook as a key player in the animal health sector, contributing to the well-being of animals worldwide. Meet Norbrook's team to gain insights into the expertise driving their innovation and market strategy. The company employs between 1,000 and 5,000 individuals, reflecting its substantial operational scale and capacity. Generating revenue of $543.1M, Norbrook demonstrates robust financial performance within the competitive pharmaceutical landscape. Its strategic focus on veterinary pharmaceuticals, coupled with a commitment to quality and innovation, underpins its market standing. Norbrook competes with major industry players such as Zoetis and Dechra Pharmaceuticals, leveraging its established expertise and product pipeline to maintain its competitive edge. The company's dedication to advancing animal health solutions through scientific rigor and market understanding solidifies its role in the global veterinary pharmaceutical industry.